ES2114051T3 - Quelantes a base de poliamina modificada por carboxamida y complejos radiactivos y conjugados. - Google Patents

Quelantes a base de poliamina modificada por carboxamida y complejos radiactivos y conjugados.

Info

Publication number
ES2114051T3
ES2114051T3 ES93912349T ES93912349T ES2114051T3 ES 2114051 T3 ES2114051 T3 ES 2114051T3 ES 93912349 T ES93912349 T ES 93912349T ES 93912349 T ES93912349 T ES 93912349T ES 2114051 T3 ES2114051 T3 ES 2114051T3
Authority
ES
Spain
Prior art keywords
carboxamide
conjugates
polyamine modified
radioactive complexes
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93912349T
Other languages
English (en)
Inventor
William J Kruper Jr
William A Fordyce
A Dean Sherry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Chemical Co
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Application granted granted Critical
Publication of ES2114051T3 publication Critical patent/ES2114051T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Paper (AREA)

Abstract

SE DESCRIBE UN GRUPO DE "QUELATORES" MODIFICADOS DE POLIAMINOCARBOXAMIDA FUNCIONALIZADOS, QUE FORMAN COMPLEJOS CON IONES METALICOS DE TIERRAS RARAS. LOS COMPLEJOS, COVALENTEMENTE UNIDOS A UN ANTICUERPO O FRAGMENTO DE ANTICUERPO, PUEDEN USARSE CON FINES TERAPEUTICOS Y/O DE DIAGNOSTICOS.
ES93912349T 1992-04-24 1993-04-23 Quelantes a base de poliamina modificada por carboxamida y complejos radiactivos y conjugados. Expired - Lifetime ES2114051T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/874,244 US5310535A (en) 1992-04-24 1992-04-24 Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies
PCT/US1993/003844 WO1993021963A2 (en) 1992-04-24 1993-04-23 Carboxamide modified polyamine chelators and radioactive complexes and conjugation

Publications (1)

Publication Number Publication Date
ES2114051T3 true ES2114051T3 (es) 1998-05-16

Family

ID=25363311

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93912349T Expired - Lifetime ES2114051T3 (es) 1992-04-24 1993-04-23 Quelantes a base de poliamina modificada por carboxamida y complejos radiactivos y conjugados.

Country Status (17)

Country Link
US (2) US5310535A (es)
EP (1) EP0637253B1 (es)
JP (1) JP3850870B2 (es)
KR (1) KR100245941B1 (es)
AT (1) ATE164522T1 (es)
AU (1) AU674853B2 (es)
CA (1) CA2134092C (es)
DE (1) DE69317771T2 (es)
DK (1) DK0637253T3 (es)
ES (1) ES2114051T3 (es)
FI (1) FI944973A7 (es)
GR (1) GR3026533T3 (es)
HU (1) HU222761B1 (es)
NO (1) NO304552B1 (es)
NZ (1) NZ252867A (es)
SG (1) SG49756A1 (es)
WO (1) WO1993021963A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6099856A (en) 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5811127A (en) 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
ES2244367T3 (es) 1993-04-22 2005-12-16 Emisphere Technologies, Inc. Composiciones para la administracion por via oral.
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6461643B2 (en) * 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US6090958A (en) 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
WO1997010197A1 (en) 1995-09-11 1997-03-20 Emisphere Technologies, Inc. METHOD FOR PREPARING φ-AMINOALKANOIC ACID DERIVATIVES FROM CYCLOALKANONES
US6007819A (en) * 1995-10-17 1999-12-28 Dovetail Technologies, Inc. Methods of inducing immunity using low molecular weight immune stimulants
AU2595697A (en) * 1996-03-29 1997-10-22 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU3828597A (en) 1996-06-14 1998-01-07 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US6358504B1 (en) * 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5939381A (en) 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5804688A (en) 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6060513A (en) 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5876710A (en) 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5990166A (en) 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5863944A (en) 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
ATE309197T1 (de) 1999-02-05 2005-11-15 Emisphere Tech Inc Verfahren zur herstellung alkylierter salicylamide
FR2802928B1 (fr) * 1999-12-22 2003-01-31 Air Liquide Polyazacycloalcanes eventuellement greffes sur une matrice solide, complexes organometalliques les incorporant comme ligands. utilisation desdits composes a l'extraction de metaux lourds
US6565828B2 (en) 2000-04-07 2003-05-20 Bristol-Myers Squibb Company Macrocyclic chelants for metallopharmaceuticals
US6517814B2 (en) 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
CZ20032564A3 (cs) * 2001-02-23 2004-09-15 Bristol-Myers Squibb Pharma Company Značené antagonisty receptoru makrofágového lapače pro zobrazování atherosklerosy a citlivých plaků
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
JP4912153B2 (ja) 2003-12-01 2012-04-11 イミューノメディクス、インコーポレイテッド タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法
CA2569461A1 (en) 2004-06-09 2005-12-29 Kereos, Inc. Lipophilic derivatives of chelate monoamides
CN101400661A (zh) * 2006-03-14 2009-04-01 马林克罗特公司 四氮杂大环衍生物的金属络合物
WO2010000714A2 (en) * 2008-07-04 2010-01-07 Oslo Universitetssykehus Hf Radioimmunoconjugate kit
WO2017019664A1 (en) 2015-07-28 2017-02-02 University Of Iowa Research Foundation Compositions and methods of treating cancer
US11179484B2 (en) 2016-06-24 2021-11-23 University Of Iowa Research Foundation Compositions and methods of treating melanoma
WO2019240884A2 (en) 2018-04-27 2019-12-19 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
CA3166142A1 (en) 2020-01-29 2021-08-05 Dongyoul Lee Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US5316757A (en) * 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
US5250285A (en) * 1985-05-08 1993-10-05 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4885363A (en) * 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
IT1224416B (it) * 1987-12-24 1990-10-04 Bracco Ind Chimica Spa Chelanti macrociclici e loro chelati
US5057302A (en) * 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
US5049667A (en) * 1987-04-14 1991-09-17 Guerbet S.A. Nitrogen-containing cyclic ligands
US4994560A (en) * 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8719042D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
DE68916052T2 (de) * 1988-02-03 1994-11-10 Hybritech Inc Modifizierte Haptene, nützlich als bildformendes Agens und als Arzneimittel.
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
JP2831073B2 (ja) * 1988-06-24 1998-12-02 ザ ダウ ケミカル カンパニー 大環状二官能キレート剤、その錯体及びそれらの抗体接合体
BR8907282A (pt) * 1988-12-23 1991-03-12 Dow Chemical Co Processo para preparar complexos de metal funcionalizados com isotiocianato
GB8903023D0 (en) * 1989-02-10 1989-03-30 Parker David Chemical compounds
JPH03504510A (ja) * 1989-02-10 1991-10-03 セルテック　リミテッド アザマクロサイクルおよびその製法
TW213864B (es) * 1991-08-01 1993-10-01 Squibb & Sons Inc

Also Published As

Publication number Publication date
WO1993021963A3 (en) 1993-12-09
HUT70429A (en) 1995-10-30
KR100245941B1 (ko) 2000-04-01
HK1006632A1 (en) 1999-03-05
NO944019L (no) 1994-12-12
FI944973L (fi) 1994-12-02
DE69317771D1 (de) 1998-05-07
HU222761B1 (hu) 2003-10-28
AU4292693A (en) 1993-11-29
WO1993021963A2 (en) 1993-11-11
NZ252867A (en) 1997-03-24
DE69317771T2 (de) 1998-07-30
SG49756A1 (en) 1998-06-15
AU674853B2 (en) 1997-01-16
CA2134092A1 (en) 1993-11-11
ATE164522T1 (de) 1998-04-15
NO944019D0 (no) 1994-10-21
FI944973A0 (fi) 1994-10-21
JPH07506365A (ja) 1995-07-13
KR950701231A (ko) 1995-03-23
GR3026533T3 (en) 1998-07-31
NO304552B1 (no) 1999-01-11
FI944973A7 (fi) 1994-12-02
DK0637253T3 (da) 1999-02-01
US5739323A (en) 1998-04-14
JP3850870B2 (ja) 2006-11-29
CA2134092C (en) 2003-07-29
EP0637253B1 (en) 1998-04-01
EP0637253A1 (en) 1995-02-08
US5310535A (en) 1994-05-10

Similar Documents

Publication Publication Date Title
BR8907507A (pt) Quelante bifuncional macrociclico,seus complexos e seus conjugados com anticorpos
WO1993021963A3 (en) Carboxamide modified polyamine chelators and radioactive complexes and conjugation
DE69021165D1 (de) Magnetisch abgeschirmter elektromagnetischer Schallwandler.
DK0857495T3 (da) Apparatur til behandling af et legemsorgan med magnetfeltterapi
MY104946A (en) Antigen antibody conjugate.
BR7802558A (pt) Dispositivo de transformacao magnetica de deteccao de informacoes magneticas codificadas,e processo de fabricacao do referido dispositivo
FR2307279A1 (fr) Procede et dispositif pour l'etude du sous-sol et de sa nature electro-magnetique
YU46858B (sh) Postupak za dobijanje imunoglobulinskih konjugata
IT8019012A0 (it) Strumento magnetico utile per curare l'impotenza.
FR2571173B1 (fr) Dispositif d'aimantation, notamment pour des aimants de cles et des serrures magnetiques de securite
EP0213881A3 (en) The use of amphipathic molecules for radioimaging and therapy with conjugates of monoclonal or polyclonal antibodies
FR2307414A1 (fr) Dispositif et procede pour la fabrication d'un panneau de reproduction a particules magnetiques
FI901162A7 (fi) Signaalin voimistaminen magneettisessa immunoanalyysissä inhiboimalla entsymaattista katalyysiä
NO902648D0 (no) Fremgangsmaate for fremstilling av absorbere for elektromagnetiske felt.
SU1639296A1 (ru) Устройство для защиты от помех
FR2649280B1 (fr) Dispositif de blindage pour empecher la propagation des champs electro-magnetiques
ES514180A0 (es) "mecanismo magnetico de accionamiento de puertas de 90".
IT1160912B (it) Piano elettropermanente per il bloccaggio e sbloccaggio magnetico dei pezzi di acciaio ferromagnetico
IT1083086B (it) Piano elettropermanente per il bloccaggio e sbloccaggio magnetico dei pezzi di acciaio ferromagnetico
FR2663561B2 (fr) Procede d'oxydation d'une charge oxydable et sa mise en óoeuvre.
KR890012762U (ko) 철판의 굽힘 가공을 위한 철판 예열장치

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 637253

Country of ref document: ES